Rituximab chimeric anti-CD20 monoclonal antibody treatment for refractory hemolytic anemia in patients with lymphoproliferative disorders

被引：0
|
作者：
Trapè, G [1 ]
Fianchi, L [1 ]
Lai, M [1 ]
Laurenti, L [1 ]
Piscitelli, R [1 ]
Leone, G [1 ]
Pagano, L [1 ]
机构：
[1] Univ Cattolica Sacro Cuore, Ist Ematol, Dept Hematol, I-00168 Rome, Italy
来源：
HAEMATOLOGICA | 2003年 / 88卷 / 02期
关键词：
lymphoproliferative disorders; rituximab; autaimmune hemolytic anemia;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
We administered rituximab monoclonal antibody to five patients suffering from a lymphoproliferative CD20-positive disease associated, at diagnosis or after starting treatment, with autoimmune hemolytic anemia (AIHA). After treatment with rituximab we observed an improvement of AIHA in all cases, and, in one case, improvement of the autoimmune thrombocytopenia associated with the AIHA. There were no relevant side effects.
引用
收藏
页码：223 / 225
页数：3
相关论文
共 50 条
  • [1] Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab)
    Arzoo, K
    Sadeghi, S
    Liebman, HA
    ANNALS OF THE RHEUMATIC DISEASES, 2002, 61 (10) : 922 - 924
  • [2] The use of anti-CD20 chimeric monoclonal antibody, rituximab in adult patients with treatment refractory immune thrombocytopenia
    Jacoub, J
    Mchlayeh, W
    Tabbara, I
    Dave, HP
    Siegel, R
    Schechter, GP
    BLOOD, 2004, 104 (11) : 74B - 74B
  • [3] Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab)
    Marzano, Angelo V.
    Fanoni, Daniele
    Venegoni, Luigia
    Berti, Emilio
    Caputo, Ruggero
    DERMATOLOGY, 2007, 214 (04) : 310 - 318
  • [4] Efficacy and Safety of Monoclonal Anti-CD20 Antibody Rituximab Combined Cyclophosphamide in Treatment of Refractory and Recurrent Autoimmune Hemolytic Anemia
    Shao, Zonghong
    Liu, Hong
    Xing, Limin
    Wu, Yuhong
    Qu, Wen
    Liang, Yong
    Guan, Jing
    Wang, Guojin
    Wang, Xiaoming
    Song, Jia
    Li, Lijuan
    Wang, Huaquan
    BLOOD, 2012, 120 (21)
  • [5] Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura
    Brændstrup, P
    Bjerrum, OW
    Nielsen, OJ
    Jensen, BA
    Clausen, NT
    Hansen, PB
    Andersen, I
    Schmidt, K
    Andersen, TM
    Peterslund, NA
    Birgens, HS
    Plesner, T
    Pedersen, BB
    Hasselbalch, HC
    AMERICAN JOURNAL OF HEMATOLOGY, 2005, 78 (04) : 275 - 280
  • [6] Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody)
    Dupuy, A
    Viguier, M
    Bédane, C
    Cordoliani, F
    Blaise, S
    Aucouturier, F
    Bonnetblanc, JM
    Morel, P
    Dubertret, L
    Bachelez, H
    ARCHIVES OF DERMATOLOGY, 2004, 140 (01) : 91 - 96
  • [7] Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with refractory idiopathic thrombocytopenic purpura.
    Braendstrup, P
    Pedersen, M
    Bjerrum, OW
    Nielsen, OJ
    Jensen, BA
    Clausen, NT
    Hansen, PB
    Andersen, I
    Schmidt, K
    Andersen, TM
    Peterslund, NA
    Birgens, HS
    Plesner, T
    Pedersen, BB
    Hasselbalch, HC
    BLOOD, 2003, 102 (11) : 298A - 298A
  • [8] Effective Treatment of Refractory Pulmonary Hemorrhage with Monoclonal Anti-CD20 Antibody (Rituximab)
    Fernando Pinto, Luis
    Candia, Liliana
    Garcia, Patricia
    Ignacio Marin, Juan
    Pachon, Ines
    Espinoza, Luis R.
    Marquez, Javier
    RESPIRATION, 2009, 78 (01) : 106 - 109
  • [9] Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus
    Arin, MJ
    Engert, A
    Krieg, T
    Hunzelmann, N
    BRITISH JOURNAL OF DERMATOLOGY, 2005, 153 (03) : 620 - 625
  • [10] Treatment of thrombocytopenia in refractory Evan's syndrome with anti-CD20 monoclonal antibody (Rituximab).
    Baltathakis, I
    Kakkas, I
    Karkatitaris, C
    Papasavvas, PL
    Tsionos, K
    BLOOD, 2002, 100 (11) : 82B - 82B
12345